Captrust Financial Advisors Myriad Genetics Inc Transaction History
Captrust Financial Advisors
- $30.9 Billion
- Q2 2024
A detailed history of Captrust Financial Advisors transactions in Myriad Genetics Inc stock. As of the latest transaction made, Captrust Financial Advisors holds 15,244 shares of MYGN stock, worth $265,398. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15,244
Previous 15,064
1.19%
Holding current value
$265,398
Previous $321,000
15.89%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding MYGN
# of Institutions
243Shares Held
92.8MCall Options Held
117KPut Options Held
113K-
Black Rock Inc. New York, NY15.2MShares$264 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$175 Million0.0% of portfolio
-
Wellington Management Group LLP Boston, MA8.26MShares$144 Million0.04% of portfolio
-
Camber Capital Management LP Boston, MA5.5MShares$95.8 Million3.72% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny4.4MShares$76.6 Million0.05% of portfolio
About MYRIAD GENETICS INC
- Ticker MYGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 80,634,800
- Market Cap $1.4B
- Description
- Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...